How does tigecycline act against Bacteroides fragilis at the drug target level?
Tigecycline works as a glycylcycline antibiotic. Its mechanism centers on binding to the 30S ribosomal subunit and blocking protein synthesis, which stops bacterial growth and replication. It does not specifically target anaerobic metabolism pathways; instead, it inhibits translation through ribosome binding.
How does metronidazole target Bacteroides fragilis?
Metronidazole is a nitroimidazole that is activated mainly under low-oxygen (anaerobic) conditions. In anaerobic bacteria such as Bacteroides fragilis, reduced forms of metronidazole interact with cellular components (including DNA), producing damage that leads to loss of viability. This means its activity depends on anaerobic activation rather than direct inhibition of protein synthesis by ribosome binding.
What’s the key difference: ribosome inhibition vs anaerobic DNA damage
The practical mechanistic contrast is that tigecycline inhibits bacterial protein synthesis by binding ribosomes, while metronidazole is selectively activated in anaerobic conditions and then damages intracellular targets such as DNA. So, tigecycline’s action is not dependent on anaerobic “activation,” whereas metronidazole’s antibacterial effect is tightly tied to the anaerobic environment and the chemistry of nitro reduction.
Does either drug have a “b fragilis specificity” mechanism?
Bacteroides fragilis is anaerobic, so it is well positioned to activate metronidazole through nitro reduction, which is the basis for metronidazole’s selective targeting in anaerobic infections. Tigecycline’s mechanism is more general and does not rely on the anaerobic activation step; it depends on its ability to bind the bacterial ribosome and inhibit translation.
Would resistance patterns reflect these different mechanisms?
Because the drug targets differ, resistance mechanisms also tend to differ. Tigecycline resistance more often relates to changes that affect tetracycline-class ribosome binding or drug efflux, since its target is the ribosome. Metronidazole resistance more often involves impaired nitro reduction/activation and altered anaerobic electron transfer pathways, because it needs reduction to generate toxic intermediates.